iTeos Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Net accretion of available-for-sale debt securities
Change in operating lease right-of-use assets
Fair value adjustment for preferred stock tranche rights liability
Deferred rent
Unrealized foreign exchange gain

Changes in operating assets and liabilities:
Grants receivable
Research and development tax credits receivable
Refundable income taxes
Prepaid expenses and other current assets
Accounts payable
Other accrued expenses
Accrued clinical trial costs
Accrued personnel expenses
Deferred income
Deferred revenue
Unrecognized tax benefits
Net cash used in operating activities
Cash flows from investing activities
Purchases of investments
Proceeds from maturities of investments
Purchase of property and equipment
Purchase of other assets
Net cash (used in) provided by investing activities
Cash flows from financing activities
Proceeds from initial public offering, net of underwriting discount
Series B-2 Preferred Stock
Total proceeds from initial public offering, net of underwriting discount
Payment of initial public offering costs
Series B-2 Preferred Stock
Total payment of initial public offering costs
Proceeds from issuance of Preferred Stock
Series B-2 Preferred Stock
Total proceeds from issuance of Preferred Stock
Proceeds from issuance of common stock upon exercise of options and ESPP purchase
Proceeds from grants repayable
Proceeds from issuance of common stock and warrants
Payment of offering costs
Series B-2 Preferred Stock
Total payment of offering costs

(Payment of) proceeds from grants repayable
Net cash provided by financing activities

Effects of exchange rate changes on cash, cash equivalents and restricted cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Non-cash investing and financing activities
Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering
Capital expenditure included in accounts payable
Accretion of Series B and B-2 Preferred Stock to redemption value
Settlement of preferred stock tranche right
Operating lease liabilities arising from obtaining right-of-use assets
Unrealized gain on available-for-sale securities
Offering costs previously included in prepaid expenses

Supplemental disclosure of cash flows
Cash paid for taxes

Comments